Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haruki Usuda

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Contemporary Clinical Trials|April 9, 2018
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study designTakaomi Kessoku, Kento Imajo, Takashi Kobayashi, et al.
Clinical and Translational Gastroenterology|August 24, 2022
Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled TrialYohei Kamata, Takaomi Kessoku, Tomoko Shimizu, et al.
Alimentary Pharmacology & Therapeutics|July 21, 2020
The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiotaNoboru Misawa, Takuma Higurashi, Tomohiro Takatsu, et al.
International Journal of Molecular Sciences|August 7, 2021
The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic TargetTakaomi Kessoku, Takashi Kobayashi, Kosuke Tanaka, et al.
The Lancet. Gastroenterology & Hepatology|August 18, 2020
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trialTakaomi Kessoku, Kento Imajo, Takashi Kobayashi, et al.
Trials|April 16, 2020
Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trialYohei Kamata, Takaomi Kessoku, Tomoko Shimizu, et al.
Frontiers in Endocrinology|November 15, 2021
Endotoxins and Non-Alcoholic Fatty Liver DiseaseTakaomi Kessoku, Takashi Kobayashi, Kento Imajo, et al.
Journal of Gastroenterology and Hepatology|March 12, 2021
Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver diseaseMichihiro Iwaki, Takaomi Kessoku, Anna Ozaki, et al.
Clinical and Translational Gastroenterology|May 26, 2022
Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational StudyYuki Kasai, Takaomi Kessoku, Kosuke Tanaka, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Contemporary Clinical Trials|April 9, 2018
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study designTakaomi Kessoku, Kento Imajo, Takashi Kobayashi, et al.
Clinical and Translational Gastroenterology|August 24, 2022
Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled TrialYohei Kamata, Takaomi Kessoku, Tomoko Shimizu, et al.
Alimentary Pharmacology & Therapeutics|July 21, 2020
The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiotaNoboru Misawa, Takuma Higurashi, Tomohiro Takatsu, et al.
International Journal of Molecular Sciences|August 7, 2021
The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic TargetTakaomi Kessoku, Takashi Kobayashi, Kosuke Tanaka, et al.
The Lancet. Gastroenterology & Hepatology|August 18, 2020
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trialTakaomi Kessoku, Kento Imajo, Takashi Kobayashi, et al.
Trials|April 16, 2020
Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trialYohei Kamata, Takaomi Kessoku, Tomoko Shimizu, et al.
Frontiers in Endocrinology|November 15, 2021
Endotoxins and Non-Alcoholic Fatty Liver DiseaseTakaomi Kessoku, Takashi Kobayashi, Kento Imajo, et al.
Journal of Gastroenterology and Hepatology|March 12, 2021
Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver diseaseMichihiro Iwaki, Takaomi Kessoku, Anna Ozaki, et al.
Clinical and Translational Gastroenterology|May 26, 2022
Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational StudyYuki Kasai, Takaomi Kessoku, Kosuke Tanaka, et al.
Pageof 4